IGC Provides Update on Phytocannabinoid IP Portfolio

Wednesday, November 2, 2016 1:32 PM UTC

BETHESDA, Md., Nov. 02, 2016 -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces updates for five patents related to method and treatment of pain, seizures and eating disorders utilizing a combination of Phytocannabinoid Cannabidiol (CBD) and other compounds.

Indication	Provisional Filing	PCT Filing	Subsequent Activity
Pain (Case 1)	9/16/14	9/16/15	US National Case Filed – 6/15/16
Seizures (Case 2)	6/15/15	6/14/16	US National Case Filed – 6/15/16
Seizures (Case 3)	4/1/15	4/1/16	PCT Application Published- 10/6/16
Eating Disorders (Case 4)	8/12/15	8/11/16	US and National Filing Anticipated 2/12/18
Seizures (Case 5)	6/15/16	Anticipated- 6/15/17	US and National Filing Anticipated 12/15/18

Phytocannabinoids are chemical compounds that exert a range of effects on the human body, including impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning. We have filed five provisional patents with the United States Patent and Trademark Office (“USPTO”), in the combination therapy space, for the indications of Pain, Medical Refractory Epilepsy and Cachexia as part of our intellectual property strategy focused on the phytocannabinoid based health care industry. The above table summarizes the latest corporate activities and it should be noted that there is no guarantee that filing a provisional or a non-provisional patent application will result in a successful registration with the USPTO.

As previously reported, approximately 50 million people worldwide are affected by Epilepsy (Sanders, 2003). Epilepsy is thought to be due to multiple factors that include Sodium, Potassium, GABA (gamma amino butyric acid) and NMDA (N-Methyl-d-aspartate). It is believed that to maximally control Epilepsy, modulation of one or more of these receptors is required and that mono therapy is adequate in up to 25% of patients.

The pain market represents a significant component of the healthcare system and The Journal of Pain in September 2012 reported that the annual estimated national cost of pain ranges from $560 billion to $635 billion. Additionally, The American Pain Society recommends that pain be made more visible and be categorized as the fifth vital sign.

Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. In the U.S. it is estimated that a population of approximately 1.3 million are experiencing Cachexia associated with Cancer, Multiple Sclerosis, Parkinson’s disease, HIV/AIDS and other progressive illnesses. Cancer induced Anorexia Cachexia is responsible for about 20% of all cancer deaths.

Mr. Ram Mukunda, CEO of IGC commented, “We see a significant opportunity in phytocannabinoid-based therapies and these additional filings further strengthen our current IP portfolio which encompasses the indications of Pain, Medical Refractory Epilepsy and Cachexia.”

About IGC

In the United States, we develop phytocannabinoid-based therapies. IGC has assembled a portfolio of patent filings that encompasses the indications of Pain, Medical Refractory Epilepsy and Cachexia using cannabinoids. We are based in Bethesda, Maryland.

Our website: www.igcinc.us. Twitter @IGCIR Facebook.com/IGCIR/